KYMR: Kymera Therapeutics Inc

KYMR News

• Zacks 13:54 Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
• Benzinga 12:14 Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' - iShares U.S. Financial ETF (ARCA:IYF), Gilead Sciences (NASDAQ:GILD)
• Investing 12:55 Kymera Therapeutics stock price target lowered to $65 at Brookline Capital
• Investing 08:52 Morgan Stanley initiates Kymera Therapeutics stock with Overweight rating
• Investing 07:57 Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion
• Investing 13:00 Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets
• Investing 22:46 Kymera Therapeutics (KYMR) director group buys $13.9 million in stock
• Investing 13:00 Monday’s Insider Activity: Top Buys and Sells in US Stocks
• Investing 00:18 Kymera Therapeutics: Baker Bros acquire $28.8m in shares
• Investing 14:23 Kymera price target raised to $54 from $51 at BofA on pipeline updates
• Investing 13:49 Kymera’s partnerships with Sanofi and Gilead drive value
• Investing 04:08 Kymera Therapeutics Announces Pricing of $250 Million Public Offering
• Benzinga 13:11 Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Apple (NASDAQ:AAPL), Alnylam Pharmaceuticals (NASDAQ:ALNY)
• Investing 12:37 Kymera stock price target raised to $60 from $54 at H.C. Wainwright
• Investing 20:52 Kymera Therapeutics price target lowered to $70 at Brookline Capital
• Investing 20:17 Kymera Therapeutics launches $250 million public stock offering
• Investing 20:13 Kymera Therapeutics stock falls after announcing $250 million offering
• Investing 17:30 Kymera stock falls as Jefferies lowers price target on program shifts
• Seeking Alpha 17:09 Kymera Shrugs Off Sanofi Bust With Gilead Deal - But There Are Caveats (NASDAQ:KYMR)
• Investing 14:09 Kymera stock falls as Sanofi drops IRAK4 degrader for next-gen candidate
• Benzinga 13:23 Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies - Gilead Sciences (NASDAQ:GILD), Sanofi (NASDAQ:SNY)
• Investing 11:17 Sanofi to advance Kymera’s oral IRAK4 degrader KT-485 to clinical testing
• Seeking Alpha 01:14 Tracking Baker Brothers Portfolio – Q1 2025 Update
• Investing 21:55 Kymera at Goldman Sachs Conference: Pioneering Oral Protein Degraders